!["I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/11e93c561a9ff98f731b152d7f48e6f792831864-1000x1000.jpg?w=350&fit=crop&auto=format)
|Articles|September 20, 2012
Yervoy footer
Advertisement
© 2012 Bristol-Myers Squibb Company, Princeton, NJ 08543 U.S.A.
731US12WA22001 10/12
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
3
Optimizing Surveillance Protocols After Focal Therapy for Prostate Cancer
4
Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship
5




















































